NEXT-GENERATION SEQUENCING (NGS): OUR RESULTS OF MOLECULAR PATHOLOGY MALIGNANT SOLID TUMOR PANEL

Next-generation sequencing (NGS) has been widely used in cancer development, diagnosis and treatment in recent years. It offers new possibilities for the detection of mutations in malignant solid tumors.In this study, the results of malignant solid tumors with NGS were evaluated. A total of 263 NGS cancer cases were included in the study.A total of 345 mutations were detected by the NGS 12 gene panel. The most common mutation was observed in NSCLC cases. The most common K-ras mutation was observed in all cancers. More than one mutation was detected in 71.8 % of the cases. The mutations showing the most frequent accumulation are K-ras, PIK3CA mutations. NGS, which is a fast and easy method, provides new possibilities in diagnosis, treatment and carcinogenesis in cancer cases. According to the study results, there were more than one mutation in malignant solid tumors. The selection of NGS panel should be based on the type of cancer and regional differences. In order to determine the effect of additional mutations on the treatment and prognosis in cancers with more than one mutation, studies should be conducted with a large series of cases.